Clinical and Laboratory Characteristics of Hyperprolactinemia in Children and Adolescents: National Survey
PDF

Original Article

Clinical and Laboratory Characteristics of Hyperprolactinemia in Children and Adolescents: National Survey

J Clin Res Pediatr Endocrinol 2019;11(2):149-156 DOI: 10.4274/jcrpe.galenos.2018.2018.0206
, , , , , ,
PDF
Permissions

Abstract

Objective:

We aimed to report the characteristics at admission, diagnosis, treatment, and follow-up of cases of pediatric hyperprolactinemia in a large multicenter study.

Methods:

We reviewed the records of 233 hyperprolactinemic patients, under 18 years of age, who were followed by different centers. The patients were divided as having microadenomas, macroadenomas, drug-induced hyperprolactinemia and idiopathic hyperprolactinemia. Complaints of the patients, their mode of treatment (medication and/or surgery) and outcomes were evaluated in detail.

Results:

The mean age of the patients with hyperprolactinemia was 14.5 years, and 88.4% were females. In terms of etiology, microadenomas were observed in 32.6%, macroadenomas in 27%, idiopathic hyperprolactinemia in 22.7% and drug-induced hyperprolactinemia in 6.4%. Other causes of hyperprolactinemia were defined in 11.3%. Common complaints in females (n=206) were sorted into menstrual irregularities, headaches, galactorrhea, primary or secondary amenorrhea and weight gain, whereas headache, gynecomastia, short stature and blurred vision were common in males (n=27). Median prolactin levels were 93.15 ng/mL, 241.8 ng/mL, 74.5 ng/mL, 93.2 ng/mL, and 69 ng/mL for microadenomas, macroadenomas, idiopathic hyperprolactinemia, drug-induced hyperprolactinemia, and other causes of hyperprolactinemia, respectively. Of 172 patients with hyperprolactinemia, 77.3% were treated with cabergoline and 13.4% with bromocriptine. 20.1% of the patients with pituitary adenomas underwent pituitary surgery.

Conclusion:

We present the largest cohort of children and adolescents with hyperprolactinemia in the literature to date. Hyperprolactinemia is more common in females and cabergoline is highly effective and practical to use in adolescents, due to its biweekly dosing. Indications for surgery in pediatric cases need to be revised.

Keywords: Pituitary, prolactin, children, microadenomas, macroadenomas, cabergoline, surgery

Read the full text

5 sections · 5 figures · PDF

Create your free account to read the full text.

  • Full text with figures and tables
  • PDF and supplementary files
  • Access on every Galenos journal
Get free access

Already have an account?

Sign in
or
Continue with Google

One Galenos account works on every Galenos journal site.

References

1

Torner L. Actions of Prolactin in the Brain: From Physiological Adaptations to Stress and Neurogenesis to Psychopathology. Front Endocrinol (Lausanne) 2016;7:25.

2

Bernard V, Young J, Chanson P, Binart N. New insights in prolactin: pathological implications. Nat Rev Endocrinol 2015;11:265-275. Epub 2015 Mar 17.

3

Rosenbloom AL. Hyperprolactinemia with antipsychotic drugs in children and adolescents. Int J Pediatr Endocrinol 2010;2010. Epub 2010 Aug 24

4

Saranac L, Zivanovic S, Radovanovic Z, Kostic G, Markovic I, Miljkovic P. Hyperprolactinemia: different clinical expression in childhood. Horm Res Paediatr 2010;73:187-192. Epub 2010 Mar 3

5

Hoffmann A, Adelmann S, Lohle K, Claviez A, Müller HL. Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. Eur J Pediatr 2018;177:125-132. Epub 2017 Nov 22

6

Watanabe S, Akutsu H, Takano S, Yamamoto T, Ishikawa E, Suzuki H, Matsumura A. Long-term results of cabergoline therapy for macroprolactinomas and analyses offactors associated with remission after withdrawal. Clin Endocrinol (Oxf) 2017;86:207-213. Epub 2016 Oct 11

7

Eren E, Yapıcı Ş, Çakır ED, Ceylan LA, Sağlam H, Tarım Ö. Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases. J Clin Res Pediatr Endocrinol 2011;3:65-69. Epub 2011 Jun 8

8

Catli G, Abaci A, Bober E, Büyükgebiz A. Clinical and diagnostic characteristics of hyperprolactinemia in childhood and adolescence. J Pediatr Endocrinol Metab 2013;26:1-11.

9

Törel Ergür A, Odabaşı Güneş S, Tan S, Tandırcıoğlu ÜA. Intracranial Lesions in Children and Adolescents with Morbid Obesity. Balkan Med J 2017;34:108-112.

10

Neyzi O, Bundak R, Gökçay G, Günöz H, Furman A, Darendeliler F, Baş F. Reference values for weight, height, head circumference, and body mass index in Turkish children. J Clin Res Pediatr Endocrinol 2015;7:280-293.

11

Klibanski A. Clinical practice. Prolactinomas. N Engl J Med 2010;362:1219-1226.

12

Nishioka H, Haraoka J, Akada K. Growth potential of prolactinomas in men: is it really different from women? Surg Neurol 2003;59:386-390.

13

Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998;83:2777-2780.

14

Lippi G, Plebani M. Macroprolactin: searching for a needle in a haystack? Clin Chem Lab Med 2016;54:519-522.

15

Kasum M, Orešković S, Čehić E, Šunj M, Lila A, Ejubović E. Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia. Taiwan J Obstet Gynecol 2017;56:719-724.

16

Bernard V, Bouilly J, Beau I, Broutin I, Chanson P, Young J, Binart N. Germline prolactin peceptor mutation is not a major cause of sporadic prolactinoma in humans. Neuroendocrinology 2016;103:738-745.

17

Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, Drummond RS, van der Merwe PA, Klenerman P, Bountra C, Thakker RV . Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med 2013;369:2012-2020. Epub 2013 Nov 6

18

Salenave S, Ancelle D, Bahougne T, Raverot G, Kamenický P, Bouligand J, Guiochon-Mantel A, Linglart A, Souchon PF, Nicolino M, Young J, Borson-Chazot F, Delemer B, Chanson P. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab 2015;100:1177-1186. Epub 2014 Dec 22

19

Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics 2014;55:29-36. Epub 2013 Oct 18

20

Delgrange E, Maiter D, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 1996;134:454-456.

21

Katavetin P, Cheunsuchon P, Swearingen B, Hedley-Whyte ET, Misra M, Levitsky LL. Review: Pituitary adenomas in children and adolescents. J Pediatr Endocrinol Metab 2010;23:427-431.

22

Perić B, Kruljac I, Šundalić S, Pećina HI, Jović A, Štefanović M, Butorac D, Vrkljan M. Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link? Endocr Res 2016;41:200-206. Epub 2016 Feb 11

23

Delibaşı T, Arslan MS, Çakal E, Şahin M, Topaloğlu O, Tutal E, Ünsal İÖ, Karbek B, Uçan B, Güngüneş A, Karaköse M, Çalışkan M, Demirci T, Tabur G, Özbek M. Hyperprolactinemia has no effect on plasma ghrelin levels in patients with prolactinoma. J Turk Ger Gynecol Assoc 2015;16:86-90.

24

Kuneš J, Pražienková V, Popelová A, Mikulášková B, Zemenová J, Maletínská L. Prolactin-releasing peptide: a new tool for obesity treatment. J Endocrinol 2016;230:51-58.

25

Ferrari C, Mattei A, Melis GB, Paracchi A, Muratori M, Faglia G, Sghedoni D, Crosignani PG. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 1989;68:1201-1206.

26

Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, Lenane MC, Rapoport JL. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999;9:239-245.

27

Garcia EC, Naves LA, Silva AO, de Castro LF, Casulari LA, Azevedo MF. Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas. Pituitary 2013;16:189-194.

28

Oguz A, Tuzun D, Sahin M, Gul K. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment. Niger J Clin Pract 2016;19:685-687.

29

Cho EH, Lee SA, Chung JY, Koh EH, Cho YH, Kim JH, Kim CJ, Kim MS. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci 2009;24:874-878. Epub 2009 Sep 24

30

Képénékian L, Cebula H, Castinetti F, Graillon T, Brue T, Goichot B. Long-term outcome of macroprolactinomas. Ann Endocrinol (Paris) 2016;77:641-648. Epub 2016 Sep 15

31

Liu Y, Yao Y, Xing B, Lian W, Deng K, Feng M, Wang R. Prolactinomas in children under 14. Clinical presentation and long-term follow-up. Childs Nerv Syst 2015;31:909-916. Epub 2015 Mar 15

32

Zhang N, Zhou P, Meng Y, Ye F, Jiang S. A retrospective review of 34 cases of pediatric pituitary adenoma. Childs Nerv Syst 2017;33:1961-1967. Epub 2017 Jul 18

33

Smith TR, Hulou MM, Huang KT, Gokoglu A, Cote DJ, Woodmansee WW, Laws ER Jr. Current indications for the surgical treatment of prolactinomas. J Clin Neurosci 2015;22:1785-1791.

34

Donegan D, Atkinson JL, Jentoft M, Natt N, Nippoldt TB, Erickson B, Meyer F, Erickson D. Surgical outcomes of prolactinomas in recent era: Results of a heterogenous group. Endocr Pract 2017;23:37-45. Epub 2016 Sep 28